A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma

This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer.
BH-11-211
Cancer - Esophogus, Cancer
Seth Kaufman, MD

D’Amour Center for Cancer Care

3350 Main Street, Springfield MA 01199

This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer.

Participants must have confirmed esophageal cancer, HER2 positive, and no prior chemotherapy or radiation.

Rae Lynn Defeo
413-794-0255